Omeros Corporation

University of Leicester

Omeros Medical Systems, Inc.

Other

Rayner Intraocular Lenses Limited

University of California

Omerus Corporation

Rayner Surgical Limited

Rayner Surgical Group Limited

Macula Bidco Limited

Gregory A Demopulos

Jeffrey M Herz

Thomas Dudler

Hans-Wilhelm Schwaeble

Pamela A Pierce

Pamela Palmer

Clark E Tedford

Larry W Tjoelker

George A Gaitanaris

Munehisa Yabuki

W Jason Cummings

Christi L Wood

Michael Nelson

Stephen A Yencho

David A Herrin

Neil G McIlvaine

James Brian Parent

Alan Bachman

William J Allen

Patrick W Gray

Thomas L Little, Jr

George E Selecman

Gorm Bressner

Scott W Reed

Leland Ray Adams

Neil S Cutshall

Wayne Richard Gombotz

G Lawrence Thatcher

Frederick Timothy Karl

Imraan Aziz

Roberto Ciccocioppo

Hongkui Zeng

John E Bergmann

William Joseph Lambert

Charles Stewart McCall

Hui-Rong Shen

Michael Cicirelli

Hui-rong Shen

Vincent A Florio

Milton R Sigelmann

John Collins

Jose Tadeo De Castro

Wayne R Gombotz

Pamela Pierce Palmer

Kenneth M Ferguson

Alan B Bachman

Rene Onrust

John Hohmann

Nigel John Brunskill

Pamela Pierce-Palmer

Thomas A Dudler

Robert W Mericle

Nicholas R Kalayjian

Tineka J Quinton

Alexander Gragerov

Tom Dudler

Imrann Aziz

Jose Tv De Castro

John Steven Whitaker

Darrell L Tanelian

Patrick Gray

Pamela A Pierce Palmer

Pierce Palmer

Frederick T Karl

In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound. In one embodiment, the subject is a human subject suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) and requires supplemental oxygen prior to treatment and the MASP-2 inhibitory agent is administered in an amount sufficient to discontinue the need for supplemental oxygen.

Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome

The present invention provides methods for inhibiting postoperative inflammatory conditions following ophthalmologic surgical procedures by administering intraocularly during an ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory agent and an alpha-1 adrenergic mydriatic agent, such as a liquid irrigation solution of ketorolac and phenylephrine.

Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions

The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.

Stable preservative-free mydriatic and anti-inflammatory solutions for injection

In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Methods for inhibiting fibrosis in a subject in need thereof

In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.

Methods for inhibiting angiogenesis in a subject in need thereof

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Methods for treating conditions associated with MASP-2 dependent complement activation

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant

The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.

Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.

Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome

This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

Treatment of addiction and impulse-control disorders using PDE7 inhibitors

Growing community of inventors

Mercer Island, WA, United States of America

Gregory A Demopulos